4
Changes in Ownership
Karyopharm Therapeutics Inc. Filed Acc 0001209191-20-042310
Chief Executive Officer sold 15,000 shares at an average $19.27 ($289,026)
- Chief Executive Officer acquired 15,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Kauffman Michael · Chief Executive Officer
Table I: Non-derivative
5 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2020-07-10 | Exercise or conversion : show line 1 in the form | +7,500 | $4.75 | $35,640 | 562,622 | D |
| 2020-07-10 | Sale : show line 2 in the form | −7,200 | $18.98 | $136,627 | 555,422 | D |
| 2020-07-10 | Sale : show line 3 in the form | −300 | $19.71 | $5,912 | 555,122 | D |
| 2020-07-09 | Exercise or conversion : show line 4 in the form | +7,500 | $4.75 | $35,640 | 763,989 | I |
| 2020-07-09 | Sale : show line 5 in the form | −7,500 | $19.53 | $146,487 | 756,489 | I |
| Open-market sales · 15,000 sh · avg $19.27 · $289,026 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| 2020-07-10 | Exercise or conversion : show line 6 in the form Stock Option (right to buy) | −7,500 | $4.75 | 2023-09-02 | 7,500 | 333,561 | D |
| 2020-07-09 | Exercise or conversion : show line 7 in the form Stock Option (right to buy) | −7,500 | $4.75 | 2023-09-02 | 7,500 | 377,803 | I |
Loading xslF345X03/doc4.xml…